The University of Sydney, Sydney Nano Institute, Faculty of Medicine and Health, Sydney School of Pharmacy, Pharmacy and Bank Building A15, Camperdown, NSW 2006, Australia.
National Heart and Lung Institute, Imperial College London, London SW7 2AZ, UK.
J Cell Sci. 2022 Jan 1;135(1). doi: 10.1242/jcs.259166. Epub 2022 Jan 12.
Current medicine has only taken us so far in reducing disease and tissue damage. Extracellular vesicles (EVs), which are membranous nanostructures produced naturally by cells, have been hailed as a next-generation medicine. EVs deliver various biomolecules, including proteins, lipids and nucleic acids, which can influence the behaviour of specific target cells. Since EVs not only mirror composition of their parent cells but also modify the recipient cells, they can be used in three key areas of medicine: regenerative medicine, disease detection and drug delivery. In this Review, we discuss the transformational and translational progress witnessed in EV-based medicine to date, focusing on two key elements: the mechanisms by which EVs aid tissue repair (for example, skin and bone tissue regeneration) and the potential of EVs to detect diseases at an early stage with high sensitivity and specificity (for example, detection of glioblastoma). Furthermore, we describe the progress and results of clinical trials of EVs and demonstrate the benefits of EVs when compared with traditional medicine, including cell therapy in regenerative medicine and solid biopsy in disease detection. Finally, we present the challenges, opportunities and regulatory framework confronting the clinical application of EV-based products.
目前的医学在减少疾病和组织损伤方面仅取得了一定的进展。细胞自然产生的膜性纳米结构——细胞外囊泡 (EVs),被誉为下一代医学。EVs 可传递多种生物分子,包括蛋白质、脂质和核酸,这些物质可以影响特定靶细胞的行为。由于 EVs 不仅反映了其亲代细胞的组成,而且还改变了受体细胞,因此它们可用于医学的三个关键领域:再生医学、疾病检测和药物输送。在这篇综述中,我们讨论了迄今为止基于 EV 的医学所见证的变革和转化进展,重点关注两个关键要素:EV 有助于组织修复的机制(例如,皮肤和骨骼组织再生),以及 EV 早期高灵敏度和特异性检测疾病的潜力(例如,检测神经胶质瘤)。此外,我们还描述了 EV 临床试验的进展和结果,并展示了与传统医学相比 EV 的优势,包括再生医学中的细胞疗法和疾病检测中的固体活检。最后,我们提出了 EV 基产品临床应用所面临的挑战、机遇和监管框架。